Hims & Hers Health, Inc. (HIMS)
| Market Cap | 10.27B |
| Revenue (ttm) | 2.01B |
| Net Income (ttm) | 193.60M |
| Shares Out | 226.02M |
| EPS (ttm) | 0.79 |
| PE Ratio | 57.63 |
| Forward PE | 62.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,888,655 |
| Open | 45.37 |
| Previous Close | 44.06 |
| Day's Range | 45.00 - 47.24 |
| 52-Week Range | 18.33 - 72.98 |
| Beta | 2.25 |
| Analysts | Hold |
| Price Target | 37.20 (-18.17%) |
| Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $37.2, which is a decrease of -18.17% from the latest price.
News
Struggling Healthcare Stock Ripe For Bull Notes
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out...
Hims & Hers: Use This Drop Before It's Too Late
Hims & Hers has experienced a hefty sell-off in recent weeks. This sell-off was mainly caused by short-term turbulence, and I expect the company to resolve these issues in the next quarter. HIMS needs...
Hims & Hers: There's Opportunity In This Crash (Upgrade)
Hims & Hers offers a compelling "Buy" opportunity after a 30% pullback, despite recent growth concerns and insider selling. HIMS maintains strong long-term growth targets, aiming for $6.5 billion in r...
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Investors searching for the next Beyond Meat, Inc. (NYSE:BYND) — the latest poster child for explosive short squeezes — are eyeing the most shorted stocks as potential candidates for outsized rallies.
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance
I expect Hims & Hers Health, Inc. to show stabilizing ARPU around $54+ per user in Q3 despite the GLP-1 slowdown, which could signal meaningful upside to the company's conservative 2030 guidance. I'm ...
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal...
Hims & Hers Health: Roller Coaster Gift
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, in...
Why Hims & Hers stock is failing to retain menopause gains and what comes next?
Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments – a large and underserved market. However, the rally is fading...
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem
Hims & Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this ...
Hims & Hers: Ramping Up A New Billion-Dollar Segment (Rating Upgrade)
I am upgrading Hims & Hers Health, Inc. to a Buy with an $80 price target, implying 30% upside. The new 'Hers' specialty in Menopause is expected to help the company drive over $1B in Hers segment rev...
How HIMS Stock Rises To $120?
Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...
Weight-loss drugs shook up the stock market. Menopause treatments could be next.
Hims & Hers is taking aim at menopause and perimenopause in an attempt to tap in to a huge and potentially highly lucrative market.
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women's health, offering access to aff...
Hims & Hers to Offer Treatments for Menopause, Perimenopause
Hims & Hers Health said it is now providing menopause care, marking the company's latest push into hormone-replacement therapies.
Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results...
Hims & Hers: Why I'm Betting On HIMS Heading To $100
I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aimi...
How Hims & Hers founder Joe Spector turned 10 failures into $1B idea
Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite podcast. How do you break into a tough market and win?
Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor's Office
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today published a new white paper - Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety - detailing how...
Hims & Hers Looks To Close $10 ARPU Gap With Product Expansion And Partnerships
Hims & Hers is driving growth through holistic treatment plans, strategic pharma partnerships, and expanded prescription offerings to boost revenue per subscriber. HIMS' recent partnership with Marius...
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
PHILADELPHIA , Oct. 3, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) ...
Buy HIMS Stock At $56?
Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primaril...
Hims & Hers: Growth Meets FDA Scrutiny And Tariff Risks
Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuatio...
Hims & Hers Powers YieldMax's Latest Options-Based Income ETF
YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).
Hims & Hers Health: Bumpy Ride Will End
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scruti...
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.